Abstract
Background. Post-stroke cognitive impairment is a common complication of ischemic stroke with an unfavorable long-term prognosis associated with decreased functional independence and an increased risk of recurrent vascular events. Despite the established role of glutamate-mediated excitotoxicity in the formation of cognitive deficits in ischemic stroke, clinical data on the use of NMDA receptor antagonists directly in the post-stroke population remain limited. Purpose – to assess the dynamics of cognitive and functional status in patients with post-stroke cognitive impairment during 9 months of memantine therapy, as well as to conduct a critical analysis of the current literature on the pathogenesis of post-stroke cognitive impairment and clinical data on the use of memantine in vascular cognitive pathology. Materials and methods. The clinical part included 60 patients with cognitive impairment after stroke (MMSE ≤ 25 points): the main group received memantine (titration 5→20 mg/day) as part of standard therapy (n = 30), the control group received only standard therapy (n = 30). The duration of observation was 9 months; control points: 0, 3, 6, 9 months. Statistical analysis: Shapiro–Wilk test, Wilcoxon test for dependent samples, Mann–Whitney test, Cohen’s coefficient (p < 0.05). A narrative review of the literature was conducted using the MEDLINE/PubMed and Scopus databases (2021–2026; keywords: cognitive impairment after stroke, memantine, NMDA receptor, vascular cognitive impairment). Results. The groups were comparable in terms of baseline characteristics (p > 0.05). In the main group, statistically significant positive dynamics of MMSE were found at all control points: at the 9th month Δ = +2.7 points (p = 0.001; Cohen’s d = 0.74). The dynamics of the Barthel index were also significant with an increasing effect: at the 9th month Δ = +10.8 points (p < 0.001; Cohen’s d = 0.97). In the control group, statistically significant changes in MMSE and Barthel index were not recorded (p = 0.087–0.143). Between-group differences at the 9th month: MMSE +1.1 points (p = 0.041), Barthel +6.1 points (p = 0.028). Subgroup analysis revealed a statistically significant improvement in patients with mild and moderate cognitive impairment (MCI); in the severe PD subgroup, the effect did not reach statistical significance (p > 0.05). Conclusions. The addition of memantine to standard therapy was associated with modest improvements in cognitive and functional status at 9 months of follow-up, mainly in patients with mild to moderate cognitive impairment. The results obtained in our study need to be confirmed in larger randomized trials.

This publication has 13 references indexed in Scilit: